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”Olen tullut luoksesi, koska muistin, 
että omenapuun varjo on hyvin kaunis 
puutarhassasi syyskuussa, kun istumme portailla.” 
“Niin, olet matkustanut viisisataa kilometriä 
nähdäksesi omenapuun valkean ja sinisen varjon. 
Iloitsen siitä – siis istukaamme portaille.” 
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Summary 
Mulibrey nanism (muscle-liver-brain-eye nanism) is a rare growth disorder first 
described in Finland in the early 1970s. Typical clinical features of mulibrey nanism include 
prenatal-onset growth failure, progressive cardiopathy, dysmorphic facial features, failure of 
sexual maturation, and metabolic syndrome. Prior to this study, the TRIM37 gene at 
chromosome 17q23-25 was identified as the causative gene for mulibrey nanism. The gene 
encodes a 964-amino acid TRIM (tripartite motif, RING-B-box-coiled-coil) family protein of 
unknown function. Four disease-associated frameshift mutations predicting truncated proteins 
were initially identified in the gene. In this study, we set out to 1) explore the subcellular 
localization of wild-type and mutated TRIM37 proteins, 2) investigate the biochemical 
function of the protein and the effect of the patient mutations on the function, 3) identify 
proteins interacting with TRIM37, and 4) analyze the distribution of Trim37 in embryonic and 
adult mouse tissues. Moreover, novel TRIM37 mutations were sought in patient DNA samples 
in order to confirm the diagnosis of suspected mulibrey nanism in patients outside of Finland, 
and to identify the second mutation in a Finnish patient heterozygous for the major Finnish 
mutation. Five frameshift mutations and two missense mutations (p.Gly322Val, p.Leu76Pro) 
were identified in the screening. The novel missense mutations were employed in subsequent 
functional studies.  
Computer-based amino acid sequence analysis predicts that TRIM37 is a soluble (non-
transmembrane) protein containing a putative nuclear localization signal close to its carboxyl 
terminus. We found that transiently expressed TRIM37 was not targeted to the nucleus but 
localized to cytoplasmic granular structures in cultured cells. The TRIM37-positive granules 
partly co-localized with peroxisomal marker proteins. The correct subcellular localization was 
lost in a mutant protein truncated at the coiled-coil region (Finmajor patient mutation) and in 
the p.Gly322Val mutant (representing a patient missense mutation), but retained in a protein 
truncated close to the carboxyl terminus (Finminor patient mutation). Endogenous TRIM37 
immunoreactivity was detected in several cell lines and it localized to peroxisomes, as 
assessed by immunofluorescence analysis.  High-level expression of TRIM37 in various cell 
lines induced the formation of poorly soluble inclusion bodies, or aggresomes, and 
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consequent loss of staining for organellar markers. An artificial mutant protein with disrupted 
RING finger (p.Cys35Ser;Cys36Ser) and the Gly322Val mutant protein did not form 
aggresomes and were markedly more soluble that the wild-type protein, suggesting that 
aggresome formation reflects a physiological function of the wild-type protein.   
Several RING finger proteins, including members of the TRIM subfamily, act as ubiquitin E3 
ligases. This prompted us to investigate whether TRIM37 is an E3 ligase. We first transiently 
expressed TRIM37 or its mutant forms in cell culture and studied their ubiquitination by 
means of immunoprecipitation and immunoblot analysis. The results showed that both full-
length TRIM37 and its TRIM fragment are highly polyubiquitinated under such conditions. 
The polyubiquitination was diminished in the RING finger mutant (p.Cys35Ser;Cys36Ser), 
and in the p.Leu76Pro mutant (representing a novel missense mutation identified in a 
mulibrey nanism patient), implying that the modification is RING-dependent 
autoubiquitination. The results were corroborated by analyzing the ubiquitination of a 
bacterially-produced TRIM fragment in a reticulocyte lysate-based assay, and indicated that 
TRIM37 possesses ubiquitin E3 ligase activity. This finding raises the possibility that 
defective proteasomal degradation or, alternatively, defective regulatory ubiquitination of an 
as-yet-unidentified target protein underlies mulibrey nanism.       
Finally, by means of immunohistochemical staining, we analyzed the distribution of Trim37 
protein in various mouse tissues during ontogenesis. During embryonic development Trim37 
immunoreactivity was detected in many epithelial tissues, including epithelium of developing 
lung and gut, in the developing pancreas and in ganglia. In adult tissues, Trim37 staining was 
detected in the central and peripheral nervous system, adenohypophysis, adrenal medulla, and 
in distinct cell types in the digestive system. Moreover, Trim37 was very highly expressed in 
maturing spermatids and oocytes.  
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Introduction 
Initiated in the mid 1980s, the Human Genome Project (HGP) reached its first goal in 2001 
when two draft sequences of the 3-billion-base pair human genome were published 
simultaneously by the HGP and by Celera, a private company (Lander et al. 2001; Venter et 
al. 2001). One of the most unexpected results of the HGP was that the estimated number of 
protein-encoding genes in humans was reduced from as high as 100,000 to about 25,000. This 
finding has, in part, lead to the realization that much of the diversity of gene products in 
higher vertebrates has to be generated by other means, for example alternative splicing, 
multifunctional proteins and post-translational modification (Levine and Tjian 2003; Pennisi 
2005). However, the actual gene number in humans remains uncertain because new classes of 
gene-like elements, micro-RNAs and other non-protein-encoding transcripts have been 
discovered in mammals (Bartel 2004; Claverie 2005).  
The sequencing of the human genome has enormously aided in the identification of disease-
associated genes. The Online Mendelian Inheritance in Man (OMIM) database lists more than 
2000 diseases and other phenotypes the underlying genes for which are currently known. 
Positional cloning has proved a particularly efficient method in identifying disease genes 
because it does not require any prior knowledge about the gene. It is based on DNA samples 
from disease families and on polymorphic DNA markers that are utilized to localize the 
disease locus by linkage analysis (Collins 1992). The Finnish disease heritage refers to rare 
genetic disorders that are much more common in Finland than elsewhere in the world (Norio 
2003a), the result of our unusual history with small, isolated founder populations (Norio 
2003b). At the turn of the millennium, 36 diseases were classified as belonging to the Finnish 
disease heritage.  Research on the molecular genetics of the Finnish disease heritage has been 
tremendously successful, as thus far the underlying genes for all but a few of the diseases 
have been identified (www.findis.org).  
Mulibrey nanism, a peculiar growth disorder with multiorgan manifestations, is a typical 
example of the Finnish disease heritage. It is autosomal recessive, 90% of known patients are 
Finnish, and it is concentrated in late-settlement areas in Finland (Perheentupa et al. 1973; 
Norio 2003c). The underlying gene for mulibrey nanism was identified by positional cloning 
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(Avela et al. 2000). The gene, TRIM37, encodes a previously uncharacterized protein of 
unknown function. What is the normal function of this protein? How do mutations in the 
TRIM37 gene perturb the function of the protein product and lead to an unusual combination 
of both developmental and adult manifestations as is seen in mulibrey nanism? Functional 
studies, including biochemical characterization, analysis of subcellular localization and 
investigation of the tissue distribution of the defective protein aim at answering these 
questions, and are the subject of this study.        
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Review of the literature 
1. Mulibrey nanism 
1.1 Background 
Mulibrey nanism (OMIM 253250), then a new disorder to the Finnish disease heritage, was 
first described in the early 1970s (Perheentupa et al. 1970; Perheentupa et al. 1973). The 
acronym mulibrey, for muscle-liver-brain-eye, is composed on the basis of some of the 
clinical findings, i.e. muscle hypotonia, hepatomegaly, enlarged brain ventricles, and 
abnormal retinal pigmentation. Mulibrey nanism cases are typically clustered in the late-
settlement regions in Savo and northern Carelia (Lipsanen-Nyman 1986, Norio 2003c). The 
Finnish mulibrey nanism-associated founder mutation most likely arose on the shores of Lake 
Pielinen in the early 1600s (Lipsanen-Nyman 1986; Kristiina Avela, unpublished data). 
Molecular genetic studies of mulibrey nanism were initiated in the mid 1990s and resulted in 
the identification of the underlying gene in the year 2000 (Avela et al. 2000). At present, a 
total of 90 Finnish mulibrey nanism patients and nine patients from outside of Finland with a 
diagnosis confirmed by mutation analysis are known.  
Reports on various clinical aspects of mulibrey nanism, such as craniofacial dysmorphism, the 
occurrence of Wilms tumour, and ophthalmologic findings were published by Finnish authors 
during the 1970s and early 1980s (Myllärniemi et al. 1978; Tarkkanen et al. 1982). The first 
suspected mulibrey nanism patients from outside of Finland were described in 1976 
(Cumming et al. 1976; Voorhess et al. 1976).  In the early 1980s, a study was initiated to 
investigate the genealogy, incidence and clinical features of the disease, based on all known 
Finnish patients. This work resulted in a monograph thesis that confirmed the autosomal 
recessive inheritance, established areas of enrichment of the disease gene, reported novel 
clinical findings in the patients, and summarized prevailing clinical data (Lipsanen-Nyman 
1986). The clinical features and diagnostic criteria have been summarized and revised 
recently (Karlberg et al. 2004a). The revised diagnostic criteria are based on a study of 85 
Finnish mulibrey nanism patients whose clinical data were systematically analysed from birth 
to the time of diagnosis. The diagnostic signs and their prevalence are presented in Table 1.  
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MAJOR SIGNS FREQUENCY (%) 
growth failure   
(A or B or C) 
A) small for gestational age lacking 
catch-up growth 
B) height in children 2.5 SDS 
below population mean for age 
C) height in adult 3.0 SDS below 
population mean 
95
94
90
characteristic 
radiological findings  
(A or B) 
A) slender long bones with thick 
cortex and narrow medullar 
channels 
B) low and shallow (J-shaped) 
sella turcica 
93
89
characteristic 
craniofacial features 
scaphocephaly, triangular face, 
high and broad forehead, low nasal 
bridge and telecanthus 
90
characteristic ocular 
findings 
yellowish dots in retinal mid 
peripheral region 79
other mulibrey nanism in a sibling 17
MINOR SIGNS peculiar high-pitched voice 96
hepatomegaly 70
cutaneous naevi flammei 65
fibrous dysplasia of long bone 25
Table 1. Diagnostic features of mulibrey nanism. For the diagnosis, three major signs with 
one minor sign or two major signs with three minor signs are required. SDS denotes standard 
deviation score. The table is modified from Karlberg et al. (2004a).  
Silver-Russell syndrome (SRS, OMIM 180860) is another dysmorphic growth disorder 
characterised by prenatal-onset progressive growth failure (Hitchins et al. 2001). Patients with 
mulibrey nanism and SRS are both gracile with similar facial dysmorphism, which makes 
differential diagnosis important. These two conditions, however, have several distinct 
characteristics. Clinodactyly (curving of the fifth finger), small face with marked 
triangularity, micrognatia (small jaws), downturned mouth corners, and skeletal asymmetry 
with hemihypertrophy are characteristics of SRS. On the other hand, hepatomegaly, 
                                
 13
pericardial constriction or cardiomyopathy, yellow dots in ocular fundi, and fibrous dysplasia 
of long bones typical of mulibrey nanism do not occur in SRS (Hannula et al. 2001; Karlberg 
et al. 2004a).  
1.2 Clinical features 
Pregnancies of mothers carrying a fetus with mulibrey nanism, and deliveries following such 
pregnancies, are in most cases normal. The prenatal-onset growth failure in mulibrey nanism  
is clearly apparent at birth, with mean birth length SDS -3.1 and mean birth weight SDS -2.8 
in newborns (Karlberg et al. 2004a). Head circumference SDS is on average -0.5, indicating 
macrocephaly relative to the small stature of the patients (Karlberg et al. 2004a). The growth 
failure progresses in later infancy, and average length SDS drops to -4.4 at two years of age, a 
typical time of diagnosis. Nearly all (96%) mulibrey nanism patients are markedly growth-
retarded and gracile at this point. Failure to thrive and feeding difficulties are the most 
common clinical problems during infancy. In addition, the patients have a high frequency of 
upper respiratory infections and middle ear infections in infancy, and pneumonias are 
diagnosed in nearly half of the infants by the age of two years (Karlberg et al. 2004a). 
Antibody deficiency and diminished antibody response in vivo has been reported in a Dutch 
patient with suspected mulibrey nanism (Haraldsson et al. 1993).  
Typical craniofacial features (see Table 1), including triangular face, high forehead and low 
nasal bridge are present in over 90% of mulibrey nanism patients at diagnosis (Karlberg et al. 
2004a). Other features present in over half of the patients are a high-pitch voice, yellow dots 
and abnormal pigment dispersion in ocular fundi, and naevi flammei mainly in the skin of the 
lower limbs. Another common finding is hepatomegaly (enlarged liver), which develops in 
45% of the patients. Psychomotor development is within normal limits in the majority of 
mulibrey nanism patients, although one third of the patients show a mild delay in motor and 
speech development (Karlberg et al. 2004a).             
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Figure 1. Two children with mulibrey nanism showing the typical external features, i.e. 
gracile body, triangular face and low nasal bridge. The vertical scar running the length of the 
chest of the patient on the right is due to cardiac surgery performed to relieve pericardial 
constriction.     
Congestive heart failure (CHF) is the most serious feature of mulibrey nanism and the main 
factor affecting the life span of patients. Of 49 Finnish patients followed  for up to 25 years, 
51% developed CHF, 39% underwent pericardiectomy and 22% died of cardiac causes 
(Lipsanen-Nyman et al. 2003). Two thirds (12/19) of patients who undergo cardiac surgery 
gain lasting clinical benefit from the operation, while one third (6/19) eventually die of 
unrelieved or recurrent CHF.  Histopathological analysis of autopsy samples shows fibrotic 
thickening of the pericardial leaves, myocardial hypertrophy, and variable but mostly mild 
myocardial fibrosis (Lipsanen-Nyman et al. 2003).  
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1.3 Endocrinological and metabolic findings in mulibrey nanism 
Mulibrey nanism patients present defects in a number of functions that are regulated by the 
endocrine system. For example, the patients develop hypergonadotrophic hypogonadism, i.e. 
failure of sexual maturation with high gonadotropin levels (Lipsanen-Nyman 1986). The 
female patients present spontaneus pubertal development but develop signs of ovarian failure 
approximately two years after menarche. At pelvic ultrasonography, the females have small 
ovaries with only a few or no follicles (Karlberg et al. 2004b). In males, testicular hypoplasia 
and a reduced number of sperm has been observed (Lipsanen-Nyman 1986). Another finding 
related to endocrine function is elevated levels of plasma adrenocorticotropic hormone 
(ACTH) in some mulibrey nanism patients (Lipsanen-Nyman 1986). However, adrenal 
steroid hormone levels are normal or only mildly subnormal (Lipsanen-Nyman 1986), and the 
adrenocortical function appears to be normal in the patients (Karlberg N, unpublished data). 
Mulibrey nanism shares some features with peroxisomal disorders, in particular with 
peroxisomal biogenesis disorders. These include growth failure, facial dysmorphism, retinal 
pigmentary changes, muscular hypotonicity, hepatomegaly, and, in Refsum’s disease, 
cardiomyopathy (Leys et al. 1989; Sacksteder and Gould 2000). Because of the overlap of 
clinical features, the peroxisomal function in mulibrey nanism patients has been studied 
previously (Schutgens et al. 1994). In a small study involving two Finnish mulibrey nanism 
patients, the plasma concentrations of phytanic acid, pristanic acid, tri- and 
dihydroxycholestanic acid and cerotic acid were found to be within reference values. 
Moreover, the profile of very-long-chain fatty acids and de novo plasmalogen biosynthesis in 
fibroblasts derived from the patients were normal. In conclusion, no biochemical evidence of 
gross peroxisomal dysfunction in mulibrey nanism was found in this study (Schutgens et al. 
1994).  
Recently, early-onset insulin resistance in mulibrey nanism patients was reported 
(Karlberg et al. 2005b). In this study, insulin resistance was detectable already in some slim 
prepubertal children. Clinically, abdominal obesity started to appear after puberty so that 42% 
of the adults were overweight (Karlberg et al. 2005). Serum leptin, uric acid, total cholesterol, 
and triacylglycerols increased with age in the patients studied. Fatty liver and hypertension 
were frequent findings among the adolescent and adult patients. Of the adults, half had type-2 
                                
 16
diabetes, 42% had impaired glucose tolerance and 70% fulfilled the National Cholesterol 
Education Program treatment panel III (NCEP) criterion for metabolic syndrome.  
1.4 Mulibrey nanism-associated tumours 
Mulibrey nanism patients have an increased risk for both benign and malignant tumours 
(Seemanova and Bartsch 1999; Karlberg et al. 2004a). Wilms tumour (WT, OMIM 194070) is 
among the most common solid tumours of childhood, occurring in 1 in 10,000 children. The 
incidence of WT is increased in several congenital malformation syndromes and trisomies 
although the vast majority of cases are sporadic (Dome and Coppes 2002). In mulibrey 
nanism, the incidence of WT is elevated (Lipsanen-Nyman 1986). One patient has been 
reported from Finland (Similä et al. 1980) and another outside of Finland (Seemanova and 
Bartsch 1999). WT is believed to arise from embryonic cells, referred to as nephrogenic rests, 
which retain embryonic differentiation potential after birth (Beckwith 1998). Germline 
mutations in the WT1 gene and somatic mutations in the BRCA2 (a breast cancer 
susceptibility gene) and GLYPICAN 3 (encoding a heparan sulphate proteoglycan) genes have 
been identified in Wilms tumours (Haber et al. 1990; White et al. 2002; Reid et al. 2005). 
WT1 encodes a zinc finger transcription factor that is critical to normal kidney and gonad 
development. Germline mutations in a single allele of WT1 cause either Wilms tumour-
aniridia-genotourinary malformations-mental retardation syndrome or Denys-Drash 
syndrome, depending on the location of the mutation (Dome and Coppes 2002). Several 
additional chromosomal loci, including 17q12-q21,  have been associated with WT (Dome 
and Coppes 2002).  
Mulibrey nanism patients have a 55% risk of developing fibrothecomas, benign 
ovarian tumours of stromal cell origin (Karlberg et al. 2004b). The stroma of the ovary 
consists of undifferentiated mesenchymal cells and their endocrine derivatives. Ovarian 
fibromas that show differentiation towards theca cells are referred to as fibrothecomas. In 
general, the tumours become malignant in less than 1% of cases (Zhang et al. 1982). Benign 
liver tumours have been also been associated with mulibrey nanism. Histopathologically, the 
tumours resemble hamartomas with fibrosis and lipid degradation (Karlberg et al 2004). 
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2. TRIM37 - the mulibrey nanism gene 
2.1 Positional cloning of the gene 
The search for the mulibrey nanism gene was initiated with a genome-wide scan of six 
multiplex families with 240 polymorphic markers (Avela et al. 1997). A marker at 17q was 
found to give evidence of suggestive linkage. Genotyping of additional markers and the 
inclusion of new families with only one affected person defined a 7-cM region at 17q as the 
critical mulibrey nanism gene region (Avela et al. 1997). Linkage disequilibrium and 
haplotype analyzes were subsequently used to narrow the critical region down to 800 kb at 
17q22-23. In order to proceed to candidate gene analysis, a physical map of the chromosomal 
region was constructed (Paavola et al. 1999). Several apparently relevant candidate genes are 
located in the region, including the growth hormone gene, HOXB cluster, TBX2 and PNUTL2,
but they were all eventually excluded as causative genes. A disease-associated mutation was 
identified in a candidate gene corresponding to a previously uncharacterized KIAA0898 
cDNA clone (Nagase et al. 1998). The KIAA0898 cDNA includes an open reading frame of 
2892 bp, coding for TRIM37, a predicted 964-amino acid protein. The major Finnish 
mutation underlying mulibrey nanism was found to be a c.493-2A>G transition in the 3’ 
splice site of exon 7 resulting in aberrant splicing at the next AG site. The mutation predicts a 
frameshift and truncation after 10 frameshifted amino acids in the coiled-coil region of the 
protein. The minor Finnish mutation, c.2212delG, has so far been detected in only two 
Finnish patients who are compound heterozygous for this and the major mutation. Two 
additional homozygous mutations, c.838delACTTT and c.11346insA, were found in patients 
from outside of Finland. All mutations identified predict a frameshift and truncated protein 
(Avela et al., 2000). An additional TRIM37 frameshift mutation predicting a protein 
truncation has been identified in a Turkish patient (Jagiello et al. 2003).  
2.2 Expression of TRIM37 mRNA 
On the basis of Northern blot analysis, a TRIM37 transcript of approximately 4.5 kb is present 
in most human tissues studied (Avela et al. 2000; Hämäläinen et al. 2005). An additional 
transcript of 3.6 kb, generated by use of an alternative 3’ untranslated region, and encoding a 
protein identical to that encoded by the 4.5-kb transcript, is seen in the testis. Quantitative 
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real-time PCR analysis of various fetal and adult human tissues shows the highest mRNA 
expression level is the testis and brain (Hämäläinen et al. 2005). By primer extension analysis, 
several transcription initiation sites have been localized to a region between nucleotides -246 
and -373 upstream of the ATG codon. Basal promoter activity, determined by means of 
luciferase reporter assays, resides within 600 nucleotides upstream from the ATG codon of 
TRIM37 (Hämäläinen et al. 2005).  
The expression of TRIM37 during mouse and human embryogenesis has been studied by 
means of RNA in situ hybridization (Lehesjoki et al. 2001). In mice, weak diffuse expression 
is first detected at embryonic day (E) 9.5. At E11.5, expression appears in the epithelial lining 
of the oesophagus and bronchi. Between E12.5 and E14.5, TRIM37 is highly expressed in 
epithelia of ectodermal or endodermal origin, but not in neuroepithelium. Tissues showing 
high expression include epithelium of the gut and stomach, epithelium of the developing 
nephron, ductal cells of the pancreas, lens epithelium and medulla of the adrenal glands. 
Intensive expression is also found in the trigeminal, symphatetic and dorsal root ganglia, and 
in the liver. The expression pattern in 4- to 10 week-old human embryos is very similar to that 
of mouse embryos (Lehesjoki et al. 2001). Interestingly, TRIM37 is highly expressed at many 
sites of mesenchymal-epithelial interaction.  
3. TRIM family proteins 
3.1 General features 
TRIM37 is a member of the TRIM (tripartite motif or RING-B-box-coiled-Coil) subfamily of 
zinc finger proteins. At present (GenBank release 150.0, October 8, 2005), the cDNAs for 68 
TRIM family proteins have been annotated in GenBank. The classification of the TRIM 
family was presented in a paper describing a large-scale analysis of 40 TRIM proteins 
(Reymond et al. 2001). The order of the domains from the N- to C-termini is strictly 
conserved (RING, B-box 1, B-box 2, coiled-coil) within the TRIM family and throughout 
evolution, suggesting that the TRIM forms an integral functional unit (Reymond et al. 2001).   
The RING domain (finger) is cysteine-rich, zinc-binding domain found in a large number of 
eukaryotic proteins (Saurin et al., 1996). RING proteins are involved in diverse cellular 
processes such as oncogenesis, apoptosis, viral replication, organelle transport, cell-cycle 
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control and peroxisomal biogenesis. In many cases RING domains mediate protein-protein 
interactions and the formation of macromolecular complexes. The RING domain contains 
eight zinc-coordinating amino acid residues, six or seven of which are cysteines and one or 
two of which are histidines (Borden 2000; Jackson et al. 2000; Joazeiro and Weissman 2000).  
The RING domain, present in most but not all TRIM family members, is followed by an 
approximately 40-amino acid zinc-binding domain, the B-box, of which there can be one or 
two (B1 and B2). The B-box domain appears to be a critical element of the TRIM because it 
is almost exclusively found in members of this protein family (Reymond et al. 2001). Four 
amino acid residues are used for zinc coordination in the B-box and they bind one zinc atom 
in a Cys2-His2 tetrahedral arrangement. The nuclear magnetic resonance structure of the B-
box of the Xenopus Xnf7 protein has been determined. It comprises two β-strands, two helical 
turns and three extended loop regions that are different from any other zinc binding motif 
(Borden et al. 1995).  
The third element of the TRIM, the coiled-coil region, is thought to mediate homo-
oligomerization of TRIM proteins (Reymond et al. 2001). Roughly 5% of all coding 
sequences in a eukaryotic genome code for coiled-coil domains, implying that the domain is 
involved in numerous cellular processes (Gillingham and Munro 2003). Coiled-coils consist 
of at least two α-helices that wrap around each other and form a slight left-handed 
superhelical twist. The amino acid sequence which forms this structure consists of a heptad 
(seven-amino acid) repeat, in which positions 1 and 4 of the sequence are usually 
hydrophobic (Gillingham and Munro 2003). The coiled-coil region in TRIM family proteins 
is followed by a variable C-terminal sequence that may contain known domains, such as 
B30.2, NHL (NCL-1, HT2A and LIN-41) or ARF (ADP-ribosylation factor) domains.  
3.2 The TRIM37 protein 
TRIM37 possesses a typical N-terminal tripartite motif comprising a RING domain, a single 
B-box domain, and a coiled-coil region. A schematic structure of TRIM37 is shown in Figure 
2. The TRIM unit is followed by a tumour necrosis factor (TNF)-receptor-associated factor 
(TRAF) domain (Zapata et al., 2001). TRAF proteins act as signal transducers for the TNF 
receptor superfamily and the interleukin 1 receptor/Toll-like receptor superfamily, i.e. in 
cytokine signalling pathways leading to activation of the transcription factors NF-κB and AP-
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1 (Wajant et al. 2001; Chung et al. 2002). With the exception of TRAF1, TRAFs contain a 
RING domain followed by various zinc finger domains, a coiled-coil region and the C-
terminal TRAF domain. Thus, the domain structure of TRAF proteins is remarkably similar to 
the N-terminal half of TRIM37, with the exception that the B-box domains of TRIM37 are 
replaced by another type of zinc finger motif in TRAF proteins. The TRAF domain of 
TRIM37 binds six known TRAF proteins and the cytosolic domains of several TNF-family 
receptors in a GST pull-down assay (Zapata et al. 2001). However, TRIM37 does not co-
localize with TRAF2, TRAF6 or the TNF family receptors CD40, Fas and DR5 in 
immunofluorescence analysis (Zapata et al. 2001). Though the physiological relevance of 
these findings remains unclear at present, it is of interest that there is some evidence 
concerning the involvement of TNF-α in the development of central obesity and in the 
regulation of insulin sensitivity in humans and mice (Moller 2000). 
Figure 2. A schematic structure of the TRIM37 protein. The predicted domains and the 
corresponding positions of the five published mutations associated with mulibrey nanism are 
depicted on the drawing. NLS denotes a putative nuclear localization signal. According to 
Avela et al. (2000) and Zapata et al. (2001).  
The C-terminal half of TRIM37 has no obvious domain homologies and is also the least 
conserved part of the protein. There are two regions (amino acids 416-550 and 895-919) with 
high numbers of acidic amino acids (aspartate and glutamate) the significance of which is 
unknown (Avela et al. 2000). On the basis of a PSI-BLAST search, the first acidic region 
contains a 64-amino acid fragment with weak homology (28% identity) to the solute carrier 
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family 9, isoform 6 (SLC9A6) protein, a sodium/hydrogen exchanger. Two adjacent putative 
nuclear localization signals are located at amino acids 847 and 851 of TRIM37 (see Figure 2).  
3.3 TRIM family proteins in disease 
Several TRIM family proteins are implicated in the pathogenesis of diseases in humans and 
mice (summarized in Table 2). The diversity of the associated diseases suggests that the 
TRIM family proteins are also functionally diverse and involved in various different cellular 
processes.  
PROTEIN DISEASE SUBCELLULAR LOCALIZATION 
TRIM5 HIV infection cytoplasm 
TRIM18/midin X-linked Opitz syndrome microtubule 
TRIM19/PML promyelocytic leukemia (CT) nuclear bodies 
TRIM20/pyrin familial Mediterranean fever microtubule, nucleus, 
cytoplasmic speckle 
TRIM21/SSA/RO Sjögren syndrome, SLE cytoplasm, nucleus 
TRIM24/TIF murine leukemia (CT) nucleus 
TRIM25/EFP breast cancer xenograft model cytoplasm 
TRIM27/RFP thyroid carcinoma (CT) nucleus 
TRIM32 limb-girdle muscular dystrophy type 2H cytoplasm 
TRIM33 thyroid carcinoma (CT) unknown 
TRIM37 mulibrey nanism peroxisome, aggregate, 
nuclear 
Table 2. TRIM family proteins implicated in disease. Disorders involving a chromosomal 
translocation of the indicated TRIM family gene are indicated with CT. PML stands for 
promyelocytic leukemia protein, SSA for Sjögren syndrome antigen and SLE for systemic 
lupus erythematosus. The table is updated from Reymond et al. (2001).     
Two monogenic disorders with mutations in TRIM family genes, X-linked Opitz syndrome 
and familial Mediterranean fever, are discussed in more detail below (see sections 3.4 and 
3.5). Limb-girdle muscular dystrophy 2H, a mild autosomal recessive myopathy enriched in 
the Manitoba Hutterite population, is caused by a mutation in TRIM32 (Frosk et al. 2002). 
TRIM32 possesses ubiquitin ligase activity and interacts with class V myosins (El-Husseini 
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and Vincent 1999; Horn et al. 2004). TRIM19/PML and TRIM27/RFP form an oncogenic 
fusion protein with retinoic acid receptor and the RET tyrosine kinase, respectively, though 
chromosomal translocation in some promyelocytic leukaemias and thyroid carcinomas in 
humans (Takahashi et al. 1988; de The et al. 1991). TRIM21/SSA/RO has been identified as 
an autoantigen in Sjögren syndrome, an autoimmune disorder (Chan et al. 1991). A 
fascinating role for TRIM5 as a factor restricting human immunodeficiency virus (HIV) 
infection has recently emerged (Stremlau et al. 2004). HIV readily enters the cells of Old 
World monkeys but is blocked before reverse transcription. The cytoplasmic blocking factor 
has been identified as a species-specific variant of TRIM5α (Hatziioannou et al. 2004).     
3.4 TRIM18/midin and Opitz syndrome 
Opitz syndrome (OS, OMIM 300000) is a congenital disorder of midline development (Opitz 
et al. 1969). Prominent clinical features include mental retardation, dysplasia of corpus 
callosum, ocular hypertelorism, cleft-lip palate and defects of the trachea and genitourinary 
tract. Additionally, cardiac abnormalities are found in the patients (Opitz et al. 1969; Jacobson 
et al. 1998). Both an X-linked and an autosomal locus have been reported for OS (Robin et al. 
1995). The TRIM18/MID1 gene underlies the X-linked form of the syndrome, also known as 
the Opitz G/BBB syndrome or hypospadias-dysphagia syndrome (Quaderi et al. 1997). The 
gene encodes a 72-kDa microtubule-associated protein named TRIM18 or midin (Schweiger 
et al. 1999). The C-terminal part of TRIM18 comprises a fibronectin type III repeat domain 
and a B30.2 domain. The B30.2 domain is a 170-amino acid globular protein domain of 
unknown function. It is found in three very different types of proteins that include RING 
finger proteins (for example TRIM18/midin and TRIM20/pyrin), proteins with 
immunoglobulin-like folds (for example butyrophilin involved in lactation), and stonustoxin 
in the venom of the fish species Synanceia horrida (Henry et al. 1998).  
Interaction screens in yeast have identified the α4 regulatory subunit of protein phosphatase 
2A (PP2A) as a binding partner of TRIM18 (Liu et al. 2001; Trockenbacher et al. 2001). The 
domain responsible for the interaction seems to be the first B-Box of TRIM18. In transiently 
transfected cells the α4 subunit colocalizes with wild-type TRIM18 in microtubules, but in 
perinuclear aggregates with a mutant form of TRIM18 mimicking a patient mutation. 
Moreover, α4 can be co-immunoprecipitated with TRIM18. The amount of PP2A in mouse 
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embryonic fibroblasts is regulated by TRIM18 in a proteasome-dependent manner 
(Trockenbacher et al. 2001). Treatment of wild-type MEFs with a proteasome inhibitor results 
in the accumulation of polyubiquitinated forms of PP2A, while in MEFs derived from 
TRIM18-/- embryos no such accumulation is detected. Defective ubiquitination of PP2A in the 
MEFs is rescued by overexpression of TRIM18. However, direct ubiquitination of α4 by 
TRIM18 in vitro was not reported. Hypophosphorylation is observed in two-dimensional 
SDS-PAGE analysis of microtubule-associated proteins from TRIM18-/- cells, which likely 
results from hyperactivity of PP2A. Taken together these result suggest that disturbed 
microtubule dynamics could underlie the developmental defects of Opitz syndrome 
(Trockenbacher et al. 2001).     
3.5 TRIM20/pyrin and familial Mediterranean fever 
In 1944, a syndrome of benign, recurrent meningitis attacks with characteristic spinal fluid 
pleocytosis (presence of cells in the spinal fluid) was described in France (Mollaret 1944). 
The attacks were separated by symptom-free periods lasting from days to years. During the 
following decades, a condition with recurrent attacks of fever and inflammation in the 
peritoneum, synovium, or pleura was reported in several ethnic groups around the 
Mediterranean region. In 1964, Siegal reported several cases with similar symptoms among 
Ashkenazi Jews in the USA and named the disorder “Familial Paroxysmal Polyserositis” 
(Siegal 1964). Now named Familial Mediterranean Fever (FMF, OMIM249100), the 
syndrome is relatively common in several ethnic groups including Arabs, Armenians and 
Turks (FrenchFMFConsortium 1997). Amyloidosis with renal failure is a complication of the 
disease. Recurrent pericarditis has been shown in association with FMF (Ercan Tutar et al. 
2000). 
Mutations in the TRIM20/pyrin gene cause FMF (The French FMF Consortium 1997; The 
International FMF Consortium 1997). The TRIM20 protein is an atypical member of the 
TRIM family in that it lacks the RING domain. However, it harbours a B-box, coiled-coil 
region and a B30.2 domain, an arrangement typical of TRIM proteins (Reymond et al. 2001).  
The subcellular localization of TRIM20/pyrin is somewhat controversial. Initially, an 
interaction screen in yeast identified a putative component of a Golgi transport complex as an 
inretaction partner for TRIM20, suggesting localization to the Golgi complex (Chen et al. 
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2000). Shortly afterwards, characterization of a TRIM20 splice variant lacking exon 2 was 
reported. The corresponding protein isoform was shown to localize exclusively to the nucleus 
in stably transfected cells, while the full-length isoform shows a diffuse cytoplasmic 
localization (Papin et al. 2000). Another study reported that TRIM20 rather associates with 
the cytoskeleton in HeLa cells (Mansfield et al. 2001). Co-localization of TRIM20 with both 
microtubules and actin filaments was shown by immunofluorescence analysis, and pull-down 
experiments lent further support to direct interaction of TRIM20 with microtubules 
(Mansfield et al. 2001). These findings are interesting in the sense that colchicine, a 
microtubule-disrupting chemical, is an effective prophylactic treatment for FMF. It was 
proposed that TRIM20 could regulate inflammatory responses through leukocyte cytoskeletal 
organization (Mansfield et al. 2001). Concurrently, apoptotic speck protein (ASC), identified 
in a yeast two-hybrid screen, was reported as a novel interaction partner for TRIM20 
(Richards et al. 2001). TRIM20 co-localizes with ASC in cytoplasmic speckles, peculiar 
structures that have the appearance of hollow rings in confocal micrographs. The speckles do 
not stain for tubulin or actin, suggesting that they do not contain aggregated cytoskeletal 
proteins, as is the case in aggresomes. TRIM20 seems to protect HeLa cells from apoptosis 
induced by ectopic ASC expression (Richards et al. 2001). The authors suggest that regulation 
of cell survival by TRIM20 could be a component of FMF pathogenesis. These data are 
supported by results from the analysis of TRIM20-deficient mice (Chae et al. 2003). Caspase-
1 is highly activated, interleukin-1β production increased and apoptosis impaired in TRIM20-/-
macrophages. Moreover, TRIM20 competes with caspase-1 for binding to ASC (Chae et al. 
2003). 
4. Ubiquitination 
4.1 Biochemistry of ubiquitination 
Discovered in the early 1980s, ubiquitination is a post-translational protein modification in 
which a single molecule or multiple molecules of the 76-amino acid ubiquitin polypeptide is 
covalently conjugated to target proteins (Hershko et al. 1980; Pickart 2001). Ubiquitin is the 
prototype and the best characterized member of a group of eukaryotic small ubiquitin-like 
proteins that are covalently attached to other proteins for various regulatory purposes 
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(Welchman et al. 2005). These include SUMO-1, -2 and -3 (small ubiquitin-like modifier), 
NEDD8 (neural precursor cell-expressed, developmentally down-regulated 8) and many other 
more recently identified proteins. Some of the ubiquitin-like modifiers have very low 
sequence homology to ubiquitin but their three-dimensional structure forms a characteristic 
ubiquitin superfold (Welchman et al. 2005).  
Ubiquitination involves three steps, each carried out by specific enzymes, designated 
ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase 
(E3) (Pickart 2001) (see Figure 3). In the first step, E1 catalyzes the formation of a thioester 
bond between the carboxyl group of the C-terminal glycine of ubiquitin and a cysteine residue 
in the active site of the E1 enzyme. Next, the activated ubiquitin is transferred to an E2 to 
form a similar transient thioester conjugate. An E3 finally catalyzes the ligation of activated 
ubiquitin to the target protein. This results in a covalent isopeptide bond between the carboxyl 
terminus of ubiquitin and the ε-amino group of a lysine residue on the target protein. 
Ubiquitin can then be repeatedly conjugated to the Lys48 or Lys63 of the previously attached 
ubiquitin, resulting in a chain of polyubiquitin (Pickart 2001). Whether the ligation of the first 
ubiquitin and subsequent polyubiquitination are generally catalyzed by the same or separate 
E2-E3 complexes is not known (Pickart 2001). There is only one type of E1 protein in 
mammalian cells, a few dozen E2s and hundreds of E3s (Pickart 2001). As suggested by the 
large number of E3 ligases the target specificity of ubiquitination is mainly determined by the 
E3s. They can be classified into 1) HECT (homologous to E6-AP carboxyl terminus) domain 
E3s, 2) RING domain E3s and 3) PHD (plant homeo domain) E3s (Pickart 2001).   
Ubiquitination is a reversible process (Pickart 2001). Several classes of deubiquitinating 
enzymes, i.e. proteases that cleave ubiquitin chains, are known though they are poorly 
characterized compared to enzymes catalyzing the forward reaction. The two major categories 
of deubiquitinating enzymes are 1) ubiquitin C-terminal hydrolases (UCHs) and 2) ubiquitin-
specific proteases (USPs). Additionally, the OTU-domain Ub-aldehyde-binding protein 
family and the Jab1/Pad1/MPN-domain metallo-enzyme family have been suggested to 
represent new classes of deubiquitinating enzymes (Kim et al. 2003). There are a few dozen 
genes encoding predicted UCHs and more than 80 genes encoding USPs in the human 
genome (Kim et al. 2003). Ubiquitin itself is translated as a chain of multiple units or fused to 
ribosomal proteins. The main role of the UCH family proteins seems to be the cleavage of 
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ubiquitin monomers from these fusion proteins and, perhaps, editing of polyubiquitin chains 
on other proteins by a similar mechanism (Kim et al. 2003). The USP family proteins 
deubiquitinate polyubiquitinated substrates, disassemble free polyubiquitin chains and, 
similarly to UCHs, process ubiquitin precursors (Kim et al. 2003). Deubiquitinating enzymes 
are involved in numerous cellular processes from regulation of proteasome function to 
oncogenesis and transcriptional regulation (Kim et al. 2003).    
Figure 3. A schematic drawing of the ubiquitin conjugation pathway. Ubiquitin is first 
activated by an ubiquitin-activating enzyme E1; activated ubiquitin is then transferred to an 
ubiquitin-conjugating enzyme E2; an ubiquitin ligase E3 facilitates the transfer of ubiquitin 
from E2 to the protein substrate. The three major classes of E3 ubiquitin ligases are HECT 
domain, RING domain and PHD E3s. Substrates marked with a Lys48-linked polyubiquitin 
chain are targeted to 26S proteasome-mediated degradation, whereas mono- and 
multiubiquitination, ubiquitination at cysteine residues, and Lys63-linked polyubiquitination 
serve a regulatory function in endocytosis, transcription and DNA repair. The drawing is 
adapted from Gao and Karin (Gao and Karin 2005). 
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4.2 Biological functions of ubiquitination 
Like phosphorylation, ubiquitination regulates a broad range of eukaryotic cell functions (Sun 
and Chen 2004; Welchman et al. 2005). In fact, ubiquitination and phosphorylation are 
sometimes intertwined to regulate protein function, for example in the pathway that activates 
the NF-κB transcription factor (Sun and Chen 2004). As a rule of thumb, Lys48-linked 
polyubiquitination serves as a degradation signal whereas monoubiquitination, 
multiubiquitination (monoubiquitination at several sites in parallel) or polyubiquitination at 
Lys63 serve as regulatory modifications (Welchman et al. 2005) (see Figure 3). The best 
studied function regulated by ubiquitination is the degradation of denatured or misfolded 
proteins and the normal turnover of a large number of intracellular proteins. Proteins marked 
with a polymer of Lys48-linked ubiquitin chains are selectively targeted to degradation by the 
proteasome, a giant proteolytic enzyme complex present in the cytosol and nucleus (Miller 
and Gordon 2005). How proteins that are destined for ubiquitination and/or degradation are 
correctly recognized by the ubiquitination machinery is a central but as yet poorly understood 
question (Laney and Hochstrasser 1999). The half-life of a protein in vivo is dependent to 
some extent on its N-terminal residue that is recognized by a specific N-recognin protein. 
This phenomenon, called the N-end rule, is best characterized in yeast, but homologs of the 
N-end recognition proteins are present in mammals as well (Kwon et al. 1998). Otherwise, 
determinants for ubiquitination, such as specific recognition peptides or hydrophobic surface 
patches have been described in a few cases (Laney and Hochstrasser 1999).    
Monoubiquitination or a combination of mono- and polyubiquitination is known to control 
DNA repair, transcription, signal transduction and endocytosis (Welchman et al. 2005). For 
example, a fraction of the DNA replication factor proliferating cell nuclear antigen (PCNA) is 
modified by SUMO-1 at two lysines under normal conditions. DNA damage induces 
desumoylation and monoubiquitination at Lys164 of PCNA to allow it to bind to sites of 
DNA damage. The monoubiquitin can be further processed by Lys63-linked 
polyubiquitination required for subsequent error-free repair of the DNA damage (Hoege et al. 
2002; Haracska et al. 2004). Both mono- and polyubiquitination have complex roles in 
transcriptional regulation in eukaryotes. Histones themselves can be ubiquitinated, nuclear 
receptors (e.g. estrogen receptors) can be ubiquitinated and targeted for degradation, and 
transcription factors like p53 can be subject to complex parallel modifications by ubiquitin, 
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SUMO-1 and NEDD8 (Welchman et al. 2005). Recently, an important role for ubiquitination 
in the regulation of endocytosis and vesicle sorting has emerged. Several growth factor 
receptors in mammals and various transporters in yeast are mono- or multiubiquitinated, 
which promotes their internalization from the plasma membrane and sorting into a subset of 
late endosomes (Katzmann et al. 2002).  Recently, ubiquitination at cysteine instead of lysine 
residues in the cytoplasmic tails of certain MHC molecules by a viral ubiquitin ligase was 
reported (Cadwell and Coscoy 2005). The ubiquitination induces internalization of the MHC 
molecules from the plasma membrane, thus diminishing antigen presentation in infected cells 
and promoting survival of the virus.   
4.2 Disorders of ubiquitination 
Defects in all three classes of ubiquitin ligases, the RING finger, HECT and PHD ubiquitin 
ligases, and in the deubiquitinating enzyme CYLD have been associated with human disease 
(Jiang and Beaudet 2004). The HECT family ubiquitin ligase E6-AP or UBE3A was first 
identified as a mediator of papilloma virus infection-induced degradation of p53, a 
remarkable finding at the time (Scheffner et al. 1993). It was later found that the UBE3A gene 
is mutated in Angelman syndrome, a neurological disorder with severe motor and mental 
retardation. UBE3A is a rare example of an ubiquitin ligase for which a directly interacting 
substrate has been identified. The substrate molecule, identified in a yeast two-hybrid screen, 
is HHR23A, a human homolog of the yeast DNA repair protein Rad23 (Kumar et al. 1999). 
Angelman syndrome patient mutations disrupt the ability of UBE3A to ubiquitinate HHR23A 
but, interestingly, autoubiquitination activity and substrate binding are unaffected (Cooper et 
al. 2004).  
AIRE, the protein defective in autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED), a member of the Finnish disease heritage (Nagamine et al. 1997; The 
Finnish-German APECED Consortium 1997), is among the first identified ubiquitin ligases 
with the novel PHD type zinc finger. Disease-causing mutations located in the sequence 
encoding the first PHD abolish the autoubiquitination activity of the protein. Two ubiquitin-
conjugating enzymes, Ubc4 and the closely related UbcH5B, support autoubiquitination of 
AIRE (Uchida et al. 2004). 
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Familial cylindromatosis or turban tumour syndrome is a peculiar monogenic disorder with 
skin tumour susceptibility (Bignell et al. 2000). The tumours, known as cylindromas because 
of their characteristic histological appearance, are believed to arise from the eccrine or 
apocrine cells of the skin that secrete sweat and scent, respectively. Cylindromas arise 
predominantly in hairy areas of the body, with approximately 90% on the head and neck 
(Bignell et al. 2000). Mutations in the gene encoding the deubiquitinating enzyme CYLD1 
underlie familial cylindromatosis (Bignell et al. 2000; Brummelkamp et al. 2003; Kovalenko 
et al. 2003; Trompouki et al. 2003). CYLD1 inhibits activation of NF-κB transcription factors 
downstream of the tumour necrosis factor receptor family molecules CD40, EDAR, and 
XDAR. The inhibition is mediated, at least in part, by the deubiquitination and inactivation of 
TNFR-associated factor 2 (TRAF2) and, to a lesser extent, TRAF6 (Trompouki et al. 2003). 
Curiously, a pathological variant of ubiquitin itself is linked to neurodegenerative diseases 
(Jiang and Beaudet 2004). A frame-shift generated by transcriptional deletion has been 
detected in UBIQUITIN B mRNA in the brains of Alzheimer’s disease patients. As a 
consequence, affected neurons accumulate UBB(+1), a mutant ubiquitin carrying a 19-amino 
acid C-terminal extension (van Leeuwen et al. 1998). UBB(+1) is a potent inhibitor of the 
proteasome in neuronal cells, suggesting that it contributes to the neurotoxicity elicited by 
amyloid accumulation (Lindsten et al. 2002).     
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Aims of the present study 
1. To explore the subcellular localization of the TRIM37 protein and its mutant forms (I-III) 
2. To investigate the predicted ubiquitin ligase activity of TRIM37 and the effect of patient 
mutations on this activity (III) 
3. To search for TRIM37-interacting proteins by means of yeast two-hybrid screening (III, 
unpublished) 
4. To analyze the distribution of Trim37 protein in embryonic and adult mouse tissues (IV) 
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Materials and methods 
Methods used in this study are summarized below in Table 3. 
METHOD ORIGINAL PUBLICATION 
DNA cloning I, II, III, IV 
Polymerase chain reaction I, II, III, IV 
DNA sequencing I, II, III, IV 
Site-directed mutagenesis I, II, III 
Patient mutation analysis II, III 
Northern blot analysis IV 
SDS-PAGE I, II, III, IV 
In vitro translation I and this thesis 
In vitro ubiquitination assay III
Enhanced chemiluminiscence detection I, II, III, IV 
Immunoblot analysis I, II, III, IV 
Immunoprecipitation III
Cell culture I, II, III, IV 
Establishment of primary skin fibroblast cultures I
Cell fractionation I
Transient transfection of cells I, II, III, IV 
Raising of antibodies I
Antibody purification I, IV 
Immunofluorescence staining I, II, III 
Immunohistochemical staining I, IV 
Fluorescence microscopy I, II, III 
Production of GST fusion proteins III
GST pull-down assay this thesis 
Yeast two-hybrid screening III and this thesis 
Database and computer analysis I, II, III, IV 
Results and Discussion 
1. Identification of novel TRIM37 mutations (II, III) 
Novel TRIM37 mutations were sought in a Finnish patient who is heterozygous for the Finmajor
mutation, and in several non-Finnish patients who fulfilled the diagnostic criteria for mulibrey 
nanism, i.e. growth failure, characteristic dysmorphic craniofacial features, J-shaped sella 
turcica, hepatomegaly and signs of heart disease. All 24 coding exons were amplified by PCR 
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from genomic DNA and sequenced. In addition, 300 bp of the putative promoter region was 
analyzed. Altogether seven new TRIM37 mutations were identified, five of which were 
frameshift mutations predicting a truncated protein and two were missense mutations. A total 
of 190 control alleles were screened for the mutations and found to be negative. A 
heterozygous missense mutation, c.965G>T, was found in a Canadian patient who had died at 
the age of four years of renal and cardiac failure. The other mutation in this patient was a 
frameshift mutation (p.Arg471X). This is the first identified missense mutation in mulibrey 
nanism patients and predicts the amino acid change Gly322Val, located in the TRAF domain 
of the protein. The mutation is, to our knowledge, the first disease-causing TRAF domain 
mutation found in any protein.  
Another heterozygous missense mutation (c.227T>C) was identified in the Finnish patient 
who carried the Finmajor mutation. The mutation predicts the change of Leu76 to a proline 
(p.Leu76Pro). It is located in a predicted alpha-helical region between the RING finger and 
the first B-Box domain of TRIM37. It is likely that the change from leucine to the cyclic 
amino acid proline disrupts the integrity of the TRIM unit and thus may affect the function of 
both the RING and B-box domains. Few missense mutations affecting RING or B-box 
domains have been identified in TRIM family genes. In TRIM18/midin, for example, nearly 
all of the few dozen or so disease associated mutations are clustered in the C-terminal part of 
the protein, outside the TRIM unit. Only one missense mutation has been identified in the 
sequence encoding the coiled-coil region in TRIM18/midin. However, RING finger mutations 
are relatively common in other types of RING finger proteins. For example, in the gene 
encoding parkin, the protein defective in autosomal recessive juvenile parkinsonism, 
altogether six missense mutations affecting the two RING finger domains of the protein have 
been identified (Sriram et al. 2005). Mutant transcripts with missense mutations, in contrast to 
transcripts predicting truncated proteins, are more likely to be translated normally and be 
stable. Therefore, a missense mutation that causes a disease often points to a functionally 
important part of a protein. It seems that this is the case for the two novel missense mutations 
identified in TRIM37 (see below).  
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2. Characterization of the TRIM37 polypeptide and antibodies (I, III, 
unpublished) 
Polyclonal antibodies against TRIM37 were raised in rabbits by immunization with the 
synthetic peptides FPDGEQIGPEDLSFNTDENSGR (C-terminal amino acids 942-963, 
peptide C1) and SVREAKEDEEDEEKIQNEDYHHE (internal amino acids 490-512, peptide 
M1) coupled to keyhole limpet hemocyanin. A polyclonal antibody against the peptide 
SYSRKDKDQRKQQAMWRVPSD (amino acids 651-671, peptide G6), identical in human 
and mouse TRIM37, was raised in rabbits against a multiple antigen peptide. The specificity 
of the anti-TRIM37 antisera was verified by immunoblotting and immunofluorescence 
staining of cell lines transiently transfected with TRIM37 expression constructs.  
The antisera against all three TRIM37 peptides recognized a protein with an apparent 
molecular mass of 130 kDa in immunoblots (Figure 4). Additionally, the M1 antiserum 
detected protein species of ~70 kDa and ~110 kDa that were absent in non-transfected cells. 
The 70-kDa band may represent a non-specific degradation product or, a more interesting 
possibility, a fragment resulting from specific proteolytic cleavage upstream of the putative 
nuclear localization signal of TRIM37. The M1 and C1 antisera also recognized the 
transiently expressed protein in immunofluorescence analysis of paraformaldehyde fixed, 
Triton X-100-permeabilized cells. 
Figure 4.  Immunoblot and in vitro translation 
analysis of the TRIM37 polypeptide. Polyclonal 
antisera raised against (A) the C-terminal TRIM37 
peptide (C1) and (B) the internal TRIM37 peptide 
(M1) detected a band at ~130 kDa in transiently 
transfected COS-1 cells. The M1 peptide antibody 
also detected less intense bands at ~110 and ~70 
kDa. Nontransfected control lanes are shown on the 
right in panels A and B. In vitro transcription-
translation of the TRIM37 cDNA in the presence of 
[35S]methionine produced a polypeptide migrating at 
~130 kDa (C). 
Because the apparent molecular mass of full-length TRIM37, deduced from immunoblots, 
was higher than the calculated value (109 kDa), in vitro transcription-translation of TRIM37
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cDNA was performed, followed by SDS-PAGE and autoradiography. The in vitro translation 
product migrated at ~130 kDa (Figure 4), similarly to the protein expressed in COS-1 cells, 
indicating that post-translational modification, e.g. glycosylation, was likely not responsible 
for the higher-than-expected molecular mass of TRIM37. It was later found that TRIM37 is 
polyubiquitinated in COS-1 cells, which markedly affects its mobility. The stoichiometry of 
ubiquitination is low, however, and the 130-kDa form of TRIM37 does not react with a 
ubiquitin antibody in immunoblots. Thus, the discrepancy between the theoretical and 
apparent molecular weight of TRIM37 probably reflects natural amino acid composition-
dependent differences in the migration of proteins in SDS-PAGE.   
In order to characterize endogenous TRIM37 biochemically, immunoblots of lysates from 
various human and mouse tissues and cell lines were probed with the anti-TRIM37 peptide 
antibodies. Despite repeated attempts, endogenous TRIM37 could not be detected 
unambiguously by means of immunoblotting (data not shown). This suggests that the peptide 
antibodies recognize the denatured antigen poorly. A combination of low levels of the antigen 
and the relative low affinity of anti-peptide antibodies may also contribute to the failure to 
detect endogenous TRIM37 in immunoblotting. Raising antibodies against larger protein 
fragments, for example GST fusion proteins, could yield high-affinity antibodies that could 
prove more suitable for immunoblotting and immunoprecipitation. However, by means of 
immunofluorescence and immunohistochemical staining, endogenous TRIM37 
immunoreactivity was detected in several cell lines and human and mouse tissues sections, 
respectively (see sections 3.2, 6.1 and 6.2). 
3. Analysis of the subcellular localization of TRIM37 and its mutants (I, II, III) 
3.1 Subcellular localization of ectopically expressed TRIM37 and its mutants 
The subcellular localization of ectopically expressed TRIM37 and its mutant forms was 
studied using immunofluorescence analysis in transiently transfected cultured cells. For a 
summary of the wild-type and mutant expression constructs used in these experiments, and 
the subcellular localization of corresponding proteins, see Table 4.  
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CONSTRUCT PROTEIN SUBCELLULAR LOCALIZATION AUTO-UB 
TRIM37 aa 1-964 cytoplasmic granular, 
aggregate ++
TRIM37(L76P) p.Leu76Pro cytoplasmic granular +
TRIM37(SS) p.Cys35Ser;Cys36Ser cytoplasmic granular +
TRIM37(G322V) p.Gly322Val cytoplasmic homogenous +++
TRIM* aa 1-252 cytoplasmic granular, 
rings +++
TRIM(L76P)* aa 1-252 (L76P) n.d. +
TRIM(SS)* aa 1-252 (C35S;C36S) n.d. +
TRAFd aa 205-454 cytoplasmic homogenous n.a.
C-terminal half aa 417-964 nuclear, cytoplasmic homogenous n.a.
Fin-major p.Arg166fsX10 cytoplasmic homogenous -
Fin-minor p.Glu738fsX31 cytoplasmic granular, 
aggregate n.d.
Table 4. Summary of the wild-type and mutant TRIM37 expression constructs used in this 
study. TRAFd denotes TRAF domain. The column SUBCELLULAR LOCALIZATION 
refers to the localization of the protein as determined by immunofluorescence analysis of 
transiently transfected cells. The column AUTO-UB refers to the degree of autoubiquitination 
of the protein observed in COS-1 cells and additionally, with the constructs marked with (*), 
in an in vitro assay. (n.a.) not applicable, (n.d.) not determined.  
Both tagged and non-tagged TRIM37 showed a punctate cytoplasmic staining pattern when 
transiently expressed in COS-1, BHK and HeLa cells. Extended expression time lead to the 
formation of large cytoplasmic clumps or aggregates that were concentrated around the 
nucleus (perinuclear aggregates, see section 3.3). In order to identify the punctate structures to 
which TRIM37 localized, co-staining for various organellar markers was performed. On the 
basis of these experiments TRIM37 staining did not localize to late endosomes/lysosomes, 
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Golgi, endoplasmic reticulum, mitochondria or microtubules. These data are in agreement 
with the results of another group who excluded transiently expressed TRIM37 from 
mitochondria, Golgi and lysosomes (Zapata et al. 2001). However, the TRIM37-positive 
granules stained with antibodies against the peroxisomal markers SKL (Ser-Lys-Leu, 
peroxisomal targeting signal 1, PTS1) and PMP70 (peroxisomal membrane protein 70), 
suggesting that ectopically expressed TRIM37 localizes to peroxisomes. A mutant protein 
representing the Fin-major mutation (p.Arg166fsX10), and truncated at the coiled-coil region, 
localized homogenously over the cytoplasm. In contrast, a mutant protein representing the 
Fin-minor mutation (p.Glu738fsX31), truncated after amino acid 737, retained punctate 
localization and co-localized with the peroxisomal protein adrenoleukodystrophy protein 
(ALDP). The p.Gly322Val mutant showed homogenous cytoplasmic localization in 
transfected COS-1 cells, indicating that is not targeted to peroxisomes. The mislocalization of 
the p.Gly322Val mutant is unexpected because the data of Zapata et al. (2001), as well as our 
unpublished data, suggest that the TRIM domain is sufficient for correct localization of 
TRIM37. It is possible that the p.Gly322Val mutation induces a conformational change that 
affects the adjacent coiled-coil region and thus leads to loss of correct localization. The novel 
p.Leu76Pro mutant was employed later in the characterization of the TRIM37 aggregates (see 
section 3.3). It localized to granular cytoplasmic structures that were somewhat different 
morphologically from those to which the wild-type protein localized. As no co-localization 
experiments with peroxisomal or other organellar markers have yet been performed, the 
identity of the structures to which the p.Leu76Pro mutant localizes remains to be investigated.    
In order to assess the subcellular localization of transiently expressed TRIM37 biochemically, 
lysates from cells transfected with a TRIM37 expression construct were subjected to 
centrifugal fractionation and density gradient centrifugation. The light mitochondrial fraction 
(23,500g pellet) was applied on top of a discontinuous Nycodenz gradient and centrifuged to 
separate the peroxisomal fraction from mitochondria and lysosomes. In an immunoblot 
analysis of the fractions collected from the gradient, TRIM37 was enriched, relative to protein 
concentration, in the heavy peroxisomal fractions with a density of 1.22-1.25 g/ml.  
Taken together, these results suggest that ectopically expressed TRIM37 localizes to 
peroxisomes in cultured cells, and that the localization is dependent on intact TRIM and 
TRAF domains. This finding is contrary to our original hypothesis, based on computer 
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predictions that TRIM37 is a nuclear protein. However, despite the fact that the full-length 
protein never showed nuclear localization we found that the C-terminal half of TRIM37 is 
targeted mainly to the nucleus when expressed in COS-1 cells (unpublished data). This is in 
line with the data of Zapata et al. (2001) who showed similar localization results with C-
terminal TRIM37 deletion constructs. Moreover, in an immunohistochemical analysis, 
nuclear TRIM37 staining was later detected in a subset of cells in mouse tissues, such as in 
the epithelium of the stomach and small intestine (see section 6.2). These data suggest that the 
nuclear localization signal of TRIM37 may be functional under certain conditions and/or in 
certain cell types. Finally, it should be noted that considerable amounts of TRIM37 might 
actually reside in the cytosol, but such a diffuse localization is difficult to discriminate from 
the more conspicuous peroxisomal localization in immunofluorescence experiments.   
3.2 Subcellular localization of endogenous TRIM37 
In order to confirm the localization data on the ectopically expressed protein we searched for 
cell lines expressing endogenous TRIM37. Immunofluorescence staining using the two anti-
TRIM37 peptide (M1 and C1) antisera revealed granular cytoplasmic staining in baby 
hamster kidney (BHK) cells, human skin fibroblasts, human liver carcinoma (HepG2) cells 
and human intestinal smooth muscle cells. The TRIM37-positive granules were positive for 
ALDP indicating that they are peroxisomes. Primary fibroblasts derived from three mulibrey 
nanism patients lacked TRIM37 immunoreactivity, which strongly suggests that the granular 
staining observed in wild-type fibroblasts is specific. In addition to immunofluorescence 
analysis, immunohistochemical staining of various human tissues showed a granular 
cytoplasmic staining compatible with peroxisomal localization, as assessed by catalase 
staining of consecutive sections. However, it is not possible to conclude from the 
immunohistochemical data that the granular staining represents peroxisomes. Provided that 
suitable antibodies are available, immunoelectron microscopy or immunofluorescence 
staining of tissue sections could allow co-staining with marker antibodies and determination 
of the subcellular localization of TRIM37 in vivo.
In order to gain insight into the mechanisms that target TRIM37 to peroxisomes, 
immortalized fibroblasts derived from patients with known peroxisomal disorders were 
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stained with the TRIM37 antibodies. The mutant cell lines used here have different defects in 
the transport of newly translated proteins from the cytosol into the lumen of the peroxisome. 
The transport is mediated by either PTS1 (C-terminal tripeptide Ser-Lys-Leu) or PTS2 (a 
short N-terminal sequence). The cell lines included PEX1?/? cells (Zellweger syndrome, a 
generalized defect in peroxisomal matrix protein import), PEX5?/? cells (autosomal neonatal 
adrenoleukodystrophy, a defect in both PTS1- and PTS2-mediated import into peroxisomes) 
and PEX7?/? cells (rhizomelic chondrodysplasia punctata, a defect in PTS2-mediated import). 
By immunofluorescence analysis, loss of peroxisomal TRIM37 immunoreactivity was evident 
in PEX1?/? and PEX5?/? cells, whereas PEX7?/? cells showed granular cytoplasmic TRIM37 
staining similar to wild-type fibroblasts. These findings indicate that the localization of 
TRIM37 immunoreactivity to peroxisomes in cultured fibroblasts is dependent on PEX5 but 
independent of PEX7. Thus, it appears that TRIM37, which itself lacks known peroxisomal 
targeting signals, may be imported into peroxisomes as a complex with a PTS1-containing 
protein.  
Finally, primary fibroblasts derived from three mulibrey nanism patients were stained for 
peroxisomal markers to investigate if the peroxisomes are morphologically affected in 
mulibrey nanism. The fibroblasts displayed apparently normal staining for the peroxisomal 
markers PMP70 and catalase, suggesting that there is no gross defect in peroxisomal structure 
in the patient cells. Further investigation of the peroxisomal morphology and function in cell 
types that are likely to be more relevant for the mulibrey phenotype than fibroblasts is 
worthwhile in the future.  
On the basis of the subcellular localization of TRIM37 we have tentatively classified 
mulibrey nanism as a peroxisomal disorder. Because of some overlapping clinical features, 
including prenatal-onset growth failure, facial dysmorphism, hepatomegaly, pigmentary 
changes in retina and muscular weakness, the possibility of a peroxisomal defect in mulibrey 
nanism has been considered previously (Schutgens et al. 1994). Peroxisomes are single-
membrane-bound organelles present in nearly all eukaryotic cells (Sacksteder and Gould 
2000). The peroxisomal lumen contains numerous metabolic enzymes involved in β-oxidation 
of long- and very long-chain fatty acids, the biosynthesis of plasmalogens, cholesterol, and 
bile acids, as well as degradation of certain amino acids and purine (Sacksteder and Gould 
2000, see also www.peroxisome.org). In peroxisomal disorders, which can be classified into 
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peroxisomal biogenesis disorders and single-enzyme disorders, mutations in genes encoding 
protein components essential for the biogenesis of the entire organelle, or in genes encoding 
single peroxisomal enzymes, respectively, lead to a metabolic defect and subsequent clinical 
manifestations (Wanders 2004). In the case of mulibrey nanism, no metabolic defect linking 
TRIM37 and peroxisomal function has been identified as yet, and no interactions of TRIM37 
with peroxisomal proteins have yet been discovered. A striking difference between mulibrey 
nanism and peroxisomal disorders, like the Zellweger syndrome and X-linked 
adrenoleukodystophy, is that patients with mulibrey nanism are neurologically intact. Thus, 
additional biochemical and cell biological approaches, as well as more detailed clinical 
investigation, are needed to clarify the putative role of peroxisomal function in mulibrey 
nanism.    
3.3 Characterization of TRIM37 aggregates 
In transiently transfected cells with a high expression level, TRIM37 rapidly formed 
aggregates that did not stain for peroxisomal or other organellar markers. These were 
apparently similar to ribbon-like aggresomes described previously (Garcia-Mata et al. 2002). 
The tendency of transiently expressed TRIM37 to aggregate was dependent on the intact 
RING domain because a mutant protein with disrupted RING domain architecture 
(p.Cys35Ser;Cys36Ser) and the p.Leu76Pro mutant protein did not form such aggregates. 
Moreover, the p.Gly322Val mutant protein remained homogenously distributed over the 
cytoplasm in the majority of cells. In order to characterize the TRIM37 aggregates, COS-1 
cells transiently transfected with TRIM37 expression constructs were stained with antibodies 
against markers for aggresomes and inclusion bodies. The small punctate TRIM37-positive 
structures that apparently precede the perinuclear aggregates were positive for Rpt6, a subunit 
of the 26S proteasome, whereas the large perinuclear aggregates were negative. The large 
aggregates were positive for Hsp70, a cytoplasmic chaperone, and ubiquitin, both of which 
are known to associate with aggresomes (Garcia-Mata et al. 2002). Aggresomes tend to cause 
reorganization, or collapse, of vimentin filaments around the perinuclear aggresome focus. 
We detected only partial reorganization of vimentin around the TRIM37 aggregates in a 
fraction of the TRIM37-expressing cells. Though the reason for this discrepancy remains 
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unclear, aggresomes that do not trigger vimentin reorganization have been reported previously 
(Garcia-Mata et al. 2002).    
The aggresome is defined as a perinuclear region where misfolded and aggregated proteins 
are sequestered for proteasomal and/or autophagosomal degradation in situations when the 
cell’s degradative capacity is exceeded (Johnston et al. 1998; Webb et al. 2003). A dramatic 
increase in half-life and poor solubility of aggregated proteins have been reported (Johnston et 
al. 1998). For many of the TRIM family members, immunofluorescence analysis of the 
ectopically expressed proteins has demonstrated cytoplasmic speckles or aggregates that do 
not co-localize with organelle markers (Reymond et al. 2001). This suggests, together with 
our results on TRIM37, that aggresome formation, at least in conjunction with 
overexpression, is a common propensity of TRIM family proteins. Generally, aggregate 
formation by the mutant rather than the wild-type proteins has been observed in transfection 
experiments of disease-associated proteins, for example TRIM18 (Cox et al. 2000). This is 
easily conceivable as disease-associated mutant proteins are often prone to misfolding and, 
consequently, are targeted for degradation by the proteasome. What we found for TRIM37 is 
contrary to this and raises the possibility that the aggresome formation reflects a physiological 
function of TRIM37, such as interaction with the proteasomal degradation machinery. 
Although aggresomes are almost exclusively described in conjunction with ectopic expression 
and various stress conditions like proteasome inhibition, emerging data supports the existence 
of aggresome-like protein complexes under physiological conditions. For example, inducible 
nitric oxide synthase forms aggresomes in a urinary bladder papilloma cell line that expresses 
the enzyme upon cytokine stimulation (Kolodziejska et al. 2005).   
4. Analysis of TRIM37 ubiquitination (III) 
4.1 Structure of the RING domain of TRIM37 
On the basis of a BLAST search, the tripartite motif of TRIM37 shares 20-25% amino acid 
sequence identity with the other members of the TRIM family. The amino acid sequence of 
the RING domain differs from the predicted consensus sequence in that it has a lysine (K) in 
the place of the conserved histidine at position 32 (Figure 5). There are additional cysteines 
and histidines (amino acids 28, 30, 35) in close proximity, and therefore the actual identity of 
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zinc-coordinating residues remains elusive (Figure 5). The RING finger of TRIM37 has 
highest similarity to those of RAD18, HRD1, RNF5 and PEX10.  
N
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Figure 5. Schematic structure of TRIM37 and the TRIM fragment used in the ubiquitination 
experiments, and the amino acid sequence of the RING domain. The positions of mutations in 
the mutant proteins used in the ubiquitination experiments are marked above the schematic 
structure. In the amino acid sequence of the RING domain, the conserved cysteine residues 
are underlined and bolded according to a prediction using the NCBI Conserved Domain 
Search (www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml). Note the lysine (K32) in the 
position that normally has a conserved histidine residue.  
4.2 Analysis of TRIM37 autoubiquitination in cultured cells 
The RING domain is essential for ubiquitin E3 ligase activity in several proteins (Pickart 
2001). RING-dependent autoubiquitination, i.e. ligation of ubiquitin to the molecule itself (in 
cis), or to an adjacent molecule on a homodimer/multimer (in trans), is an indication of E3 
ligase activity. For a summary of the results of the ubiquitination assays presented here and in 
sections 4.3 and 4.4, see Table 4. In order to investigate the putative E3 activity of TRIM37, 
the ubiquitination of full-length TRIM37 or its TRIM fragment in COS-1 cells was studied. 
Various TRIM37 expression constructs and a hexahistidine-ubiquitin expression plasmid 
were co-transfected into COS-1 cells. Ubiquitinated proteins were subsequently enriched 
from the cell lysates by use of nickel affinity chromatography and guanidium hydrochloride 
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lysis. The recovery from this enrichment method was low, probably due to the poor solubility 
and hydrophobicity of the ectopically expressed protein. Therefore, immunoprecipitation by 
means of an aminoterminal HA tag was subsequently used to enrich the protein. This allowed 
cell lysis in 0.4% SDS and apparently total solubilization of the ectopically expressed protein, 
which also diminishes the possibility of deubiquitination and protein degradation after lysis. 
To avoid interference from immunoglobulin chains in subsequent immunoblot analysis, an 
affinity matrix with covalently bound anti-HA IgG was used for the immunoprecipitation of 
the TRIM fragment. The immunoprecipitates were analyzed by immunoblotting. Probing the 
blots with an anti-ubiquitin antibody showed the presence of a high-molecular-mass 
ubiquitin-positive smear in the TRIM fragment samples. Accumulation of ubiquitinated 
species was markedly decreased in a mutated TRIM fragment in which two adjacent cysteines 
at a conserved zinc-binding position were mutated to serines (p.Cys35Ser;Cys36Ser). 
Reprobing of the filters with an HA antibody showed the non-modified TRIM fragment at 
~30 kDa and, in the presence of ubiquitin, a ladder of high-molecular-mass protein. 
Ubiquitination of full-length TRIM37 was studied in COS-1 cells using a similar 
experimental approach, except that successful immunoprecipitation of full-length TRIM37 
required the presence of N-ethylmaleimide, a chemical that alkylates cysteine residues. 
Immunoblot analysis showed accumulation of high-molecular-mass ubiquitinated TRIM37 in 
the immunoprecipitates. The mutant protein with a disrupted RING domain 
(p.Cys35Ser;Cys36Ser) showed markedly decreased ubiquitination. Reprobing of the filter 
with an HA antibody showed a high-molecular-mass smear representing polyubiquitinated 
TRIM37.  
4.3 Analysis of TRIM37 autoubiquitination in vitro
In order to rule out the possibility that the polyubiquitination of TRIM37 observed in intact 
cells was a result of aggregate formation and subsequent proteasomal degradation, 
ubiquitination of bacterially-produced glutathione-S-transferase (GST)-TRIM fusion proteins 
was studied in vitro (for a summary of the results see Table 4). Rabbit reticulocyte lysate, a 
source of ubiquitin-activating enzyme and several ubiquitin-conjugating enzymes, is used as a 
cell-free system to study ubiquitination (Hershko et al. 1980). Due to its poor solubility, 
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purification of the GST-TRIM fusion protein from bacteria according to the standard protocol 
did not succeed as extraction from bacteria expressing the GST-TRIM fusion proteins with 
1% Triton X-100 yielded only minute amounts of soluble protein. However, addition of the 
ionic detergent N-lauroylsarcosine at a concentration of 1.5% in the lysis buffer, followed by 
3% Triton X-100, dramatically improved the yield and was subsequently used for all 
purifications. Full-length TRIM37 could not be produced in bacteria, probably due to its 
relatively large size and poor solubility.   
For the in vitro ubiquitination assay, wild-type GST-TRIM fusion protein and its mutant 
forms (p.Cys35Ser;Cys36Ser and p.Leu76Pro) bound to glutathione sepharose beads, were 
incubated in reaction mixtures containing nuclease-treated rabbit reticulocyte lysate, 
ubiquitin, ATP, MgCl2, ZnSO4, DTT and the proteasome inhibitor MG-132. The samples 
were analyzed by immunoblotting using antibodies against ubiquitin or GST. In this assay, 
wild-type GST-TRIM was polyubiquitinated in a RING domain-dependent manner verifying 
the result from transfection experiments. This strongly suggests that the ubiquitination 
detected in intact cells and in the cell-free assay is, indeed, RING-catalyzed 
autoubiquitination and indicative of ubiquitin E3 ligase activity.  
Further evidence to support the participation of TRIM37 in protein ubiquitination was 
obtained from a yeast two-hybrid screen using the TRIM fragment as bait (see also section 5). 
Of the clones that were in the correct reading frame with the GAL4 activation domain, four 
clones encoded ubiquitin and two clones encoded ubiquitin-ribosomal fusion proteins. In 
contrast, with the TRAF domain or the C-terminal half of TRIM37 as bait, no ubiquitin-
encoding clones were identified. We further tested whether the E2 enzyme UbcH5 could 
support autoubiquitination of GST-TRIM in vitro, but the result was negative. Yeast two-
hybrid screens also failed to disclose an interacting E2 for TRIM37. Thus, identification of a 
specific E2 that functions with TRIM37 to catalyze ubiquitin transfer awaits further study. 
4.4 Effect of patient mutations on TRIM37 autoubiquitination 
The identification of the first two mulibrey nanism-associated missense mutations prompted 
us to study the effect of the various patient mutations on the autoubiquitination of TRIM37. 
We first found that, in COS-1 cells, autoubiquitination of TRIM37 was completely abolished 
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in a protein representing the Fin-major mutation, truncated at the coiled-coil region. This 
finding is compatible with the hypothesis that coiled-coil region-mediated oligomerization is 
essential for the function of TRIM family protein (Reymond et al. 2001). Further, similarly to 
the artificial RING domain mutant (p.Cys35Ser;Cys36Ser), the p.Leu76Pro mutant protein 
affecting the TRIM unit showed markedly decreased autoubiquitination. It is likely that the 
Leu76Pro amino acid change affects the integrity of both the RING and B-Box domains thus 
leading to diminished autoubiquitination. The p.Leu76Pro mutation had a similar effect to the 
autoubiquitination of a GST-TRIM fusion protein in an in vitro assay. In contrast, the 
p.Gly322Val mutant protein was ubiquitinated similarly to the wild-type protein. The 
Gly322Val amino acid change is located in the TRAF domain and is unlikely to disturb the 
TRIM unit, which explains the unaffected autoubiquitination of this mutant protein. It is 
tempting to speculate that even though the p.Gly322Val mutation does not affect the 
autoubiquitination activity of TRIM37 it may affect the ubiquitination of the actual 
(unidentified) substrate because of a disrupted TRAF domain-mediated protein-protein 
interaction.   
In conclusion, the ubiquitination experiments strongly suggest that TRIM37 functions as an 
ubiquitin E3 ligase. The fact that the autoubiquitination of TRIM37 demonstrated in these 
experiments is polyubiquitination does not allow a conclusion to be drawn about the nature of 
the actual substrate ubiquitination, i.e. if it is mono- or polyubiquitination. Ubiquitin ligase 
activity has not been demonstrated in any mammalian peroxisomal proteins, but in yeast, the 
peroxisomal membrane protein Pex4p acts as a ubiquitin-conjugating enzyme (Crane et al. 
1994), suggesting that ubiquitination takes place at the peroxisomal membrane. In fact, it has 
been shown recently that yeast Pex5p is polyubiquitinated at the peroxisomal membrane and 
thereby targeted for proteasomal degradation, which may serve as a quality control system in 
peroxisomal biogenesis (Platta et al. 2004; Kiel et al. 2005). Additionally, yeast Pex18p is 
known to be subject to mono- and diubiquitination (Purdue and Lazarow 2001). There are 
three peroxisomal transmembrane proteins (PEX2, PEX10, and PEX12) that each harbour a 
RING domain facing the cytosol, but they have not been reported to possess E3 ligase 
activity. How the ubiquitin ligase activity of TRIM37 is associated with a peroxisomal 
function remains to be investigated. Nevertheless, dysregulated ubiquitin-dependent 
proteolysis has previously been implicated in several inherited disorders (Jiang and Beaudet 
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2004). Ubiquitination may also serve other functions than protein degradation. For example, 
monoubiquitination has been shown to regulate membrane protein trafficking, endocytosis, 
and the function of diverse proteins including histones and transcription factors (Schnell and 
Hicke 2003). Therefore, identification of the substrates for TRIM37 ubiquitin ligase activity 
will be crucial for understanding the molecular pathways that are affected in mulibrey nanism.       
5. Identification of TRIM37-interacting proteins (III, unpublished) 
Because the cellular pathway(s), signalling route(s) or structural protein complex(es) to which 
TRIM37 may belong are not known, we set out to search for proteins interacting with 
TRIM37 by means of yeast two-hybrid screening. The yeast two-hybrid screens were 
performed according to the Fields’ method (Fields and Song 1989). cDNA fragments
encoding amino acids 1-252 (TRIM), 205-454 (TRAF) or 417-964 (C-terminus) of human 
TRIM37 were used as baits.  
With the TRIM bait a total of 42 positive yeast colonies, some of which contained two 
different prey plasmids, were obtained. Sequencing of the recovered plasmids yielded 38 
sequences, of which 18 were in the correct reading frame with GAL4. Probably due to the 
intrinsic properties of the TRIM bait the efficiency of the screen was relatively low, and a 
total of only 200 000 colonies were screened, while the recommended minimum is one 
million colonies. With the TRAF domain bait only four positive yeast colonies, all of which 
contained the same cDNA fragment, were obtained. With the C-terminal bait 37 positive 
yeast colonies were obtained. Sequencing yielded 13 sequences, of which eight were in the 
correct reading frame with GAL4. A list of the putative interaction partners of TRIM37 found 
in the screens is presented in Table 5. Some of the putative interactions are discussed in more 
detail below.  
                                
 46
BAIT CLONES IDENTITY PULL-DOWN
TRIM N6,15,42  ubiquitin B n.d.
“ N9 NICE-3 +
“ N10,22,26 ribosomal-ubiquitin fusion n.d.
“ N12,34 UBE3A ubiquitin ligase n.d.
“ N14,39,40 vitamin D-binding protein n.d.
“ N20 SULT1A2 variant +
“ N27 RNU2 n.d.
“ N28 REA / prohibitin 2 +
“ N33 elongation factor EEF1A1 n.d.
“ N35 predicted chaperone n.d.
“ N37 transferrin n.d.
TRAF M1,2,3,4 predicted mitochondrial protein n.d.
C-term. C5 cyclin G1-binding protein 1 n.d.
“ C6 human factor X n.d.
“ C9 RPS7 ribosomal protein n.d.
“ C13 activating transcription factor 5 n.d.
“ C17 MCRS1 n.d.
“ C20 RING finger protein 10 -
“ C32 ABCB6 mitochondrial transporter +
“ C35 clusterin -
Table 5. Putative protein interactions of TRIM37 identified in yeast two-hybrid screens. The 
first column indicates the TRIM37 fragment used as a bait in the screen. Some of the putative 
interactions have been further studied by means of GST pull-down experiments (PULL-
DOWN). Plus (+) denotes a positive result in GST pull-down assays. (n.d.) not determined. 
In the yeast two-hybrid screens, the TRIM bait picked up several clones encoding ubiquitin or 
ubiquitin-ribosomal protein fusions (see Table 5), which is in agreement with the ubiquitin 
ligase activity of TRIM37. Moreover, two clones with cDNA fragments that encode the 
HECT domain of the UBE3A ubiquitin ligase, implicated in Angelman syndrome, were 
recovered in the screen. This interaction, as well as the others listed in Table 5, remains to be 
verified in further studies. The TRIM bait also picked up two cDNAs that encode proteins 
with C-terminal tripeptides similar to PTS1 (unpublished data), which prompted us to inspect 
these clones further. One of the cDNAs encodes a putative splice variant of hast4/SULT1A2
cDNA. Cytosolic sulphotransferases (SULTs) are enzymes that catalyze sulfonation, an 
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important step in the metabolism of many drugs, xenobiotics, neurotransmitters, and steroid 
hormones (Kauffman 2004).  The C-terminus of SULT1A2, SEL (Ser-Glu-Leu), differs by 
only one amino acid from the consensus PTS1 (SKL, Ser-Lys-Leu). However, it is unlikely 
that SEL functions as a PTS1 because the lysine of SKL is replaced by the negatively charged 
glutamic acid (Emanuelsson et al. 2003). GST pull-down experiments confirmed that both the 
alternative isoform encoded by the yeast clone and full-length SULT1A2 (hast4 and hast4v) 
bind the TRIM fragment of TRIM37 (Figure 6).  
Figure 6. GST pull-down verification of a the 
putative TRIM37-SULT1A2 interaction. 
Various SULT cDNAs were translated in vitro
and the reaction products were incubated with 
GST-TRIM protein coupled to glutathione-
sepharose beads. The beads were washed and 
the bound proteins were analyzed by means of 
immunoblotting with an antibody against an HA 
tag (unpublished data). Both the alternative 
isoform encoded by the yeast clone (A, 
SULT1A2 variant) and full-length SULT1A2 
(A, hast4 and hast4v) bind the TRIM fragment 
of TRIM37. The closely related enzymes 
SULT1A1, SULT1A3 and SULT1C1 did not 
bind the TRIM fragment, and neither did a green fluorescent protein (GFP) control (B). 
The other protein with a PTS1-like sequence identified in the TRIM bait screen was NICE-3. 
This is an uncharacterized protein with homology to 6-phosphogluconate dehydrogenase, an 
enzyme of the pentose phosphate pathway. The C-terminal tripeptide of NICE-3 is STL (Ser-
Thr-Leu). It is unlikely that STL could function as a PTS1 either because of the unusual 
amino acid, threonine at position 2. NICE-3 also bound to the TRIM fragment in a GST pull-
down assay (data not shown).  
Three clones encoding mitochondrial proteins (prohibitin 2, an uncharacterized B30.2-
domain protein and ABCB6) were found in the yeast two-hybrid screens (unpublished data, 
see Table 5). Prohibitin 2 is a peculiar protein that apparently localizes to both the nucleus, 
where it functions as a transcriptional regulator, and to mitochondria where it may function as 
a chaperone and regulator of cellular senescence (Mishra et al. 2005). GST pull-down 
experiments verified that the TRIM fragment binds prohibitin 2 in vitro (data not shown). In 
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the TRAF domain bait screen all four positive clones contained the same ~1.3-kb fragment of 
an uncharacterized cDNA encoding a predicted B30.2-domain protein with a 28-amino acid 
N-terminal mitochondrial leader sequence. The third mitochondrial protein fragment found in 
the screens, with the C-terminal TRIM37 bait, was the ATP-binding domain of ABCB6. This 
interaction was verified by a GST pull-down assay (data not shown). ABCB6 is a 
mitochondrial membrane protein belonging to the ABC transporter family (Mitsuhashi et al. 
2000).  
The pleiotrophic clinical manifestations in mulibrey nanism, and the fact that the molecular 
pathway(s) to which TRIM37 belongs are as yet unknown, make the evaluation of the 
significance of the interactions presented above difficult. Interaction screens in yeast are 
prone to false positives and, therefore, extensive verification of the putative interactions by 
other methods has to be performed. One of the more rigorous methods to confirm an 
interaction between two proteins under physiological conditions is co-immunoprecipitation of 
the endogenous proteins. This requires that antibodies suitable for immunoprecipitation are 
available, which is not the case for TRIM37 and many of the putative interacting proteins 
listed in Table 5. Nevertheless, as technically challenging as it may be, further analysis of the 
interactions could shed light on the function of TRIM37 and on the pathways that are 
defective in mulibrey nanism.       
6. Distribution of Trim37 in mouse tissues (IV) 
6.1 Distribution of Trim37 in embryonic tissues 
Expression of TRIM37 during early and middle stages of embryonic development, up to E15 
in mice, has been studied previously by means of in situ hybridization (Lehesjoki et al. 2001). 
In order to gain further insight into the expression of the Trim37 gene during ontogenesis, we 
analyzed the distribution of Trim37 mRNA and protein in mouse tissues by Northern blot 
analysis and immunohistochemical staining, respectively. For the immunohistochemical 
analysis, antigen affinity-purified fractions of the anti-human TRIM37 antisera (raised against 
the M1 peptide) were used. Antigen retrieval by a 15-minute microwave heating in citrate 
buffer produced a drastic increase in the staining intensity and was included in the staining 
protocol. To further enhance the staining intensity in some tissues, tyramide signal 
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amplification (Adams 1992) was utilized. The overall distribution of the Trim37 protein in 
embryonic tissue was very similar to that reported for the Trim37 mRNA (Lehesjoki et al. 
2001), lending further support to the specificity of the antibody.  
By immunohistochemical analysis, a weak staining for Trim37 appeared at E9.0, the earliest 
stage analyzed. At E10-E12.5, epithelial Trim37 staining in many tissues became apparent. 
Highest staining was observed in the heart, the somites, surface ectoderm of the embryo, and 
the developing esophagus and lung. At E15.5 strong epithelial Trim37 staining was observed 
in the intestine, kidney and tips of the developing pancreatic buds. The surface ectoderm and 
dorsal root ganglia were intensely positive for Trim37, whereas the liver showed a weak 
diffuse staining. Taken together, Trim37 is highly expressed in many neural crest-derived 
tissues and in several epithelia, particularly at sites of mesenchymal-epithelial interaction 
during mouse embryonic development.   
6.2 Distribution of Trim37 in adult mouse tissue 
Tissues included in the mulibrey acronym 
Expression of Trim37 was detected in all muscle types, including smooth muscle, skeletal 
muscle and heart muscle. Among the muscles studied, the expression was highest in the 
muscle of the abdominal wall, in which the staining was apparently fiber-specific and striated 
(Figure 7A). The only manifestation of mulibrey nanism relating to the skeletal muscle is 
mild hypotonia. It is implausible that the muscular hypotonia is related to the expression of 
Trim37 in the muscle. Rather, it likely reflects a mild neurological dysfunction, as has 
previously been suggested (Karlberg et al. 2004a). It may, for example, be a result of 
disturbed Trim37 function in the ganglia that innervate muscles, and showed intense Trim37 
staining in mouse tissues.  
A relatively weak nuclear Trim37 staining was detected in the mouse liver (Figure 7B), which 
is in contrast to the granular cytoplasmic staining that was previously (Kallijärvi et al. 2002) 
observed in human liver sections. This discrepancy could be explained by a species-specific 
difference in the distribution of the protein. Nuclear Trim37 staining was even more evident 
in some other tissues than the liver, for example in the oesophagus and stomach, suggesting 
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that the two predicted NLSs in mouse Trim37 are functional in certain cell types or under 
certain conditions.  
Intense Trim37 staining was detected in restricted neuronal cell populations in many regions 
of the brain (data not shown). Mulibrey nanism patients have normal intelligence, but show 
mild structural defects in the central nervous system (CNS), i.e. enlarged ventricles and basal 
cisternas, as well as mild neurological symptoms, including muscle hypotonia and a mild 
delay in motor and speech development (Karlberg et al. 2004). In the light of our 
immunohistochemical findings it is somewhat surprising that the patients clinically display 
only minor neurological defects.  
In the retina (Figure 7C), Trim37 staining was detected in the photoreceptor layer (pr) and, to 
a lesser extent, in the inner (ip) and outer (op) plexiform layers, and nerfe fibre layer (nf) that 
comprise processes of photoreceptor cells and neurons. Yellowish dots in retinal mid 
peripheral region are one of the major diagnostic signs of mulibrey nanism (Karlberg et al. 
2004). In addition, atrophy of the corneal epithelium, thickening of the Bowman's membrane, 
and atrophy of the retina and of the pigment epithelium has been reported (Tarkkanen et al. 
1982).  The high cell-layer specific expression of Trim37 could account for the ocular 
changes present in mulibrey nanism patients. Interestingly, the vision is only modestly, if at 
all affected in these patients.   
The digestive system 
Intense Trim37 staining was observed in many tissues of the digestive system. The mucinous 
acini of the salivary gland stained intensely for Trim37 while the serous part was almost 
negative (Figure 7D). Goblet cells along the gastrointestinal tract stained intensely for Trim37 
(Figure 7E). Moreover, nuclear Trim37 was observed in the epithelium of the esophagus and 
stomach. In the stomach, the nuclear staining was strongest towards the base of the gastric 
glands (Figure 7F). Intense Trim37 staining was also observed in enteric ganglia in stomach 
and all parts of the intestine from duodenum to colon (data not shown). Half of mulibrey 
nanism patients suffer from poor feeding during infancy, presenting as vomiting and a delay 
in switching to solid food (Karlberg et al. 2004). Interestingly, the feeding difficulties 
disappear in the great majority of the patients during early childhood. In the light of the 
Trim37 expression pattern in the digestive system, it is tempting to speculate that functions 
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regulated by enteric ganglia (e.g. bowel movement) or a function performed by the goblet 
cells (e.g. secretion of mucus), or both, contribute to the feeding difficulties in infants with 
mulibrey nanism. 
The endocrine organs 
Strong Trim37 staining was detected in a subset of cells in the adenohypophysis, the 
endocrine part of the pituitary gland (Figure 7G). The identity of the Trim37-expressing cell 
type remains to be investigated. Intense Trim37 staining was also detected in the adrenal 
medulla, while the adrenal cortex was negative (Figure 7H). The staining was present in most 
but not all cells of the adrenal medulla, suggesting that it is cell-type specific. Trim37 mRNA 
is also restricted to the medulla in the developing adrenal gland in embryonic mice (Lehesjoki 
et al. 2001). Elevated levels of plasma ACTH is seen in mulibrey nanism but the 
adenocortical function appear to be normal (Karlberg N, unpublished data). The strong 
expression of Trim37 that we dectected in a subset of unknown cell in the pituitary gland of 
the mouse, however, is not contradictory to the clinical presentation. Adrenal medullary cells 
are modified postganglionic neuronal cells that secrete mainly catecholamines (the 
sympathoadrenal system). The serum levels of catecholamines are normal in mulibrey nanism 
patients and no changes have been noted in the adrenal medulla (Karlberg N et al., 
unpublished data). However, recent data show that the adrenal medulla also secretes peptide 
hormones, for example pancreastatin that inhibits glucose uptake and activates hepatic 
glycogenolysis in humans (O'Connor et al. 2005). The expression of Trim37 in both the 
adrenal medulla and endocrine pancreas, combined with recent clinical data showing that 
subjects with mulibrey nanism develop severe insulin resistance and metabolic syndrome 
early in adulthood (Karlberg et al. 2005), is of great interest. Te exact identity of the Trim37-
positive cells in the endocrine tissues is an important subject of further study that could shed 
light on the pathogenetic mechanism underlying mulibrey nanism. 
The gonads 
In post-pubertal testis, a stage-specific cytoplasmic staining of spermatids was detected 
(Figure 7I). Developing sperm from type B spermatogonia to early spermatids were strongly 
                                
 52
positive, while the rest of the cell types in the testis, including Leydig cells, Sertoli cells and 
spermatogonia, were negative. In post-pubertal ovary, intense Trim37 staining was detected in 
the oocytes. Staining was also present in the granulosa cells, luteal gland, and in the 
epithelium of the fallopian tube (data not shown). Female patients with mulibrey nanism 
present incomplete sexual maturation and develop premature ovarian failure. Their uteri and 
ovaries are small and only a few or no follicles are present in ultrasonography (Karlberg et al 
2004b). In males, testicular hypoplasia and a reduced number of sperm has been encountered 
(Lipsanen-Nyman M, unpublished data). Interestingly, the highest level of Trim37 mRNA is 
detected in the testis in both humans (Avela et al. 2000; Hämäläinen et al. 2005) and mice 
(see above). In post-pubertal mouse testis, we detected a strong stage-specific Trim37 staining 
of the germ cell cytoplasm. Our immunohistochemical findings in mouse gonads are in 
agreement with the clinical findings seen in postpubertal males and females with mulibrey 
nanism.  
In summary, the tissue distribution of Trim37 during ontogenesis suggests that it has a 
function in many neural crest-derived tissues. These include the adrenal medulla and 
sympathetic and parasympathetic nerves. Moreover, the facial dysmorphism typical of 
mulibrey nanism points to a function of human TRIM37 in the development of the 
craniofacial cartilage and bone that are derived from the neural crest as well (Helms and 
Schneider 2003). The high expression of Trim37 that was detected in a subset of the 
presumably hormone-secreting cells of the adenohypophysis suggests that Trim37 plays a role 
in the regulation of an endocrine function. Trim37 may also be important for the function of a 
number of secretory cell types in the salivary glands and in the intestine, as well as for 
sympathoadrenal function and gametogenesis.  
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Figure 7. Immunohistochemical analysis of the distribution of Trim37 in various organs of 
adult mice. Skeletal muscle from the abdominal wall (A) shows an apparently fibre-specific 
staining that is striated when inspected at a higher magnification (inset). In the liver (B), a 
weak nuclear staining was observed in the hepatocytes (inset). The retina (C) was intensely 
positive for Trim37. The staining was strongest in the photoreceptor layer (pr) but was also 
present in the inner (ip) and outer (op) plexiform layers and in the nerve fibre layer (nf). 
Intense Trim37 staining was detected in many tissues of the digestive system (D-F). The 
mucinous acini and the excretory ducts of the salivary glands were strongly positive (D). In 
the duodenum (E) a strong staining of the goblet cells (arrow heads) and intestinal ganglia 
(arrows) emerged. In the stomach (F) nuclear Trim37 staining in the epithelium was observed 
(arrows). The adenohypophysis (G) shows an intense staining in a subset of the cells that is 
mainly cytoplasmic. The adrenal medulla (H, me), the neuroendocrine part of the adrenal 
gland, was among the most intensively Trim37-positive tissues, while the adrenal cortex (co) 
was essentially negative. Within the adrenal medulla there was heterogeneity in the staining 
pattern, with a minority of the cells showing weak staining. In the round spermatids in the 
testis, Trim37 staining was detected in the polarized cytoplasm (I).  Magnification is 630X in 
I, 200X in the other figures, and 1000X in the insets.  
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Conclusions and future prospects
In this study the functional characterization of the TRIM37 protein was initiated. The work 
aims at understanding the molecular pathogenetic mechanisms that underlie mulibrey nanism, 
a peculiar pleiotrophic disorder with a number of distinct clinical features that become 
manifest at different time points. The complexity of the clinical picture that includes 
symptoms as diverse as growth failure, cardiopathy, type-2 diabetes, and susceptibility to 
Wilms tumour, raises the possibility that TRIM37 has several distinct molecular functions. 
Alternatively, it can be hypothesized that TRIM37 has a single function that serves different 
purposes depending on the cell type and developmental stage. Dissecting the function of a 
previously uncharacterized protein is, in many cases, a demanding task. Both inadequacy of 
the molecular tools available (e.g. antibodies, biologically relevant cell lines) and complexity 
of the biological processes studied may contribute to the challenge. Given that the underlying 
genes for most monogenic disorders, including mulibrey nanism, have been known for only a 
short time, further study is the only cure for this problem.  
This thesis, in which the TRIM37 protein has been viewed from several different angles, 
provides a basis towards understanding the molecular pathogenesis of mulibrey nanism. In the 
course of the study, a number of new mulibrey nanism-associated mutations were identified, 
among these the first missense mutations identified in the TRIM37 gene. The novel missense 
mutations turned out to be important for the subsequent functional studies of TRIM37. 
Furthermore, the subcellular localization of the TRIM37 protein and its mutants was 
investigated. On the basis of the localization studies we have tentatively classified mulibrey 
nanism as a peroxisomal disorder. However, the finding that nuclear Trim37 staining was 
observed in some mouse tissues and the fact that several mitochondrial proteins were 
identified as putative interaction partners for TRIM37 raise the possibility that the protein 
may localize to more than one subcellular compartment. The differential localization could 
depend on the cell type, the phase of the cell cycle, or the metabolic status of the cell. Clearly, 
more experiments are needed to clarify the role of peroxisomal function in mulibrey nanism, 
and to shed light on the significance of the other putative subcellular localizations. Analysis 
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of patient samples using high-throughput methods, such as expression profiling with cDNA 
arrays and lipid profiling with mass spectrometry, could prove useful in this respect. The 
generation of TRIM37 knock-out mice will, if the human phenotype is replicated in mice, 
likely aid the inquest into the putative metabolic defects in mulibrey nanism. 
A biochemical function, ubiquitin E3 ligase activity, was demonstrated for TRIM37 in this 
study. The finding that a patient missense mutation disrupts the ubiquitin ligase activity 
suggests that the loss of the E3 activity is crucial to the pathogenesis of mulibrey nanism. In 
the light of our findings it is tempting to speculate that the function of TRIM37 is to induce 
ubiquitin-dependent degradation of a target protein. Loss-of-function mutations in TRIM37
would thus lead to an excess of the target protein and subsequent downstream effects 
depending on the identity of the target protein. However, non-proteolytic regulatory 
ubiquitination by TRIM37 remains a possibility to be reckoned with. In any case, the 
identification of substrates of TRIM37-mediated ubiquitination is a prerequisite for the 
progression of this line of investigation. A set of putative interaction partners of TRIM37 was 
identified in yeast two-hybrid screens. While none of the interactions were solidly confirmed 
in this study, the data provide material for further functional studies. Characterization of the 
putative interacting proteins identified in this study, as well as mass spectrometric 
identification of affinity-purified proteins that bind to different parts of TRIM37, could help 
identify substrates of TRIM37.  
Immunohistochemical analysis of embryonic and adult mouse tissues indicated that Trim37 is 
expressed in a highly tissue-specific manner during ontogenesis, which suggests that it has a 
cell type-specific regulatory function rather than a general role in cell maintenance. These 
findings are in agreement with the multiorgan manifestation of mulibrey nanism. Putative cell 
type-specific functions of TRIM37, both during embryonic development and in the adult 
organism, are a fascinating area of research and could shed light on the development of the 
complex mulibrey nanism phenotype. 
The recent finding that mulibrey nanism patients are prone to develop insulin resistance and 
type 2 diabetes mellitus is of utmost interest (Karlberg et al. 2005b). There are few 
monogenic models for insulin resistance, which is why research on mulibrey nanism could 
have a great impact on the study of diabetic mechanisms. It will be interesting to see whether 
TRIM37-/- mice will phenocopy the insulin resistance of mulibrey nanism patients. Another 
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important question that remains open at present is the mechanisms that lead to tumour 
susceptibility in mulibrey nanism patients. Particularly, investigation of the mulibrey nanism-
associated Wilm’s tumours could uncover the development of this tumour type in general. 
More studies have to be conducted to clarify both the clinical, developmental and biochemical 
aspects of the disorder. Thorough understanding of the basic pathogenetic mechanisms is also 
essential for the development of therapies for mulibrey nanism in future.              
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